Oct 04, 2022 16:44 JST

Source: Eisai

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
To Strengthen its Research and Development Function for Injectable Drug Formulations

TOKYO, Oct 04, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.

External view of EMITS
 


EMITS will be Eisai's global base for formulation and modality research. In recent years, Eisai's drug discovery targets have expanded to include modalities such as antibodies, antibody drug conjugates (ADCs), and nucleic acid drugs, in addition to conventional small molecule compounds. At EMITS, Eisai will strengthen its injectable drug formulation development research function and drug delivery system (DDS) development function, including liposomal and lipid nanoparticle formulations, and address the development of various modalities. The following initiatives will be implemented.

- Elevating the quality and speed of formulation process research through introduction of a state-of-the-art manufacturing data management system and utilization of AI
- Installation of facilities that also enable the manufacturing of clinical trial materials in order to manufacture investigational injection drugs in-house
- Introduction of rapid microbial testing methods for advanced microbiological control and sterility assurance
- Enhancing collaboration with the creation of flexible space that can also be used for collaborative research with external partners and technologies

Through these efforts, Eisai aims to elevate the quality of the technology and knowledge of its formulation research function, and to become a base for disseminating innovation, technology, and solutions relating to formulations. The aggregate investment in the construction of EMITS is approximately 10 billion Japanese yen.

The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing. Through the construction of EMITS, Eisai aims to elevate the quality of its formulation research and formulation manufacturing, accelerate medicine creation activities, and ultimately further its contribution to improving the benefits of patients and their families.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2022/news202273.html.

Source: Eisai
Sectors: BioTech

Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
December 01 2022 19:09 JST
 
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 30 2022 09:21 JST
 
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
November 30 2022 08:31 JST
 
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
November 29 2022 18:28 JST
 
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
November 24 2022 08:04 JST
 
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
November 22 2022 13:10 JST
 
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 21 2022 10:50 JST
 
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
November 16 2022 10:46 JST
 
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
November 07 2022 08:15 JST
 
Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand
November 04 2022 14:42 JST
 
More Press release >>

Latest Press Release


More Latest Release >>